PHAR (Pharming Group N.V.) stock: $12.29, $868.0M market cap, $145.3M cash, $722.7M EV, $221.2M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
What they do
We focus on immunological and genetic conditions where our scientific and commercial expertise can help advance care over the long term. Patients are at the heart of everything we do. Their insights along with those of caregivers and the scientific community shape our strategy, guide our clinical study designs, and influence how we manage our approved therapies.
Cash figures as of 2025-12-31. Database snapshot: 2026-11-07.
Share structure
Common
7.0M
Pre-funded warrants
0.0M
Options
0.8M
RSUs
2.0M
Warrants
0.0M
Converts
8.1M
Conv preferred
0.0M
ESPP reserve
—
FDSO
18.0M
Cap table as of 2025-12-31.
Price history
Loading PHAR daily closes…
Loading price history…
Recently reported
leniolisib Phase 2Positive · 2026-09-22
Single-arm open-label Phase 2 in inborn errors of immunity with dysregulated PI3K signaling · primary immunodeficiencies with immune dysregulation linked to pi3k-delta signaling
Partnerships OrphanPacific (Japan supply and distribution)
Indications
activated PI3K-delta syndrome (APDS)(Approved)
Status note Approved in the US, UK, Japan, Australia and Israel; additional launches being prepared.
Per-asset detail extracted from the 20-F filed 2026-04-02. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.